Funded Project Details - FY2021
|Title:|| HCV and co-morbid alcohol use disorders: a translational investigation of antiviral therapy outcomes on CNS function|
|Congressional District Code:
||Biomedical Laboratory R&D
|| October 2018 -
|FY 2021 Funding Amount:
|Total Award Amount
View full abstract and other project information on NIH RePORTER
Go To NIH RePORTER
Chronic hepatitis C virus (HCV) infection is often associated with extrahepatic manifestations, including central nervous system (CNS) damage and neuropsychiatric impairments that can be exacerbated by alcohol abuse. More than half of patients with chronic HCV infection complain of “brain fog” (impaired cognition, fatigue). The introduction of direct-acting antiviral (DAA) therapies has revolutionized HCV treatment, with sustained viral response (SVR) rates of ~90%. The VA is now offering DAA th...
Questions about the R&D website? Email the Web Team
Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.